An Evaluation of 5-Fluorouracil in Malignant Disease

Article1 November 1961An Evaluation of 5-Fluorouracil in Malignant DiseaseARTHUR J. WEISS, M.D., LAIRD G. JACKSON, M.D., RALPH CARABASI, M.D.ARTHUR J. WEISS, M.D.Search for more papers by this author, LAIRD G. JACKSON, M.D.Search for more papers by this author, RALPH CARABASI, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-55-5-731 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptUntil recently, it was believed that preformed pyrimidines, unlike preformed purines, were not utilized by mammalian tissues, either normal or neoplastic. In 1954, Rutman, Cantarow, and Paschkis (1) observed that uracil was incorporated into preneoplastic rat liver and rat hepatoma. In 1957, Heidelberger, Leibman, Harbers, and Bhargava (2) verified this finding and noted that significant incorporation of uracil occurred into intestinal mucosa and several carcinomas of mice and rats. Because of these findings, many pyrimidine antagonists have been synthesized and evaluated for their effect in malignant disease. Of these drugs, 5-fluorouracil (3), 5-fluorodeoxyuridine (4), and 6-azauridine (5) have been subjected...References1. RUTMANCANTAROWPASCHKIS RJAKE: Studies in 2-acetylaminofluorene carcinogenesis. III. The utilization of uracil-2-C14 by preneoplastic rat liver and rat hepatoma. Cancer Res. 14: 119, 1954. MedlineGoogle Scholar2. HEIDELBERGERLEIBMANHARBERSBHARGAVA CKCEPM: The comparative utilization of uracil-2C14 by liver, intestinal mucosa, and Flexner-Jobling carcinoma in the rat. Cancer Res. 17: 399, 1957. MedlineGoogle Scholar3. CURRERIANSFIELDMCIVERWAISMANHEIDELBERGER ARFJFAHAC: Clinical studies with 5-fluorouracil. Cancer Res. 18: 478, 1958. MedlineGoogle Scholar4. YOUNGELLISONSULLIVANLEVICKKAUFMANMILLERWOLDOWESCHERLIKARNOFSKYBURCHENAL CWRRRDSNREIGMDDAJH: The clinical evaluation of 5-fluorouracil and 5-fluoro 2-deoxyuridine in solid tumors in adults. A progress report. Cancer Chemother. Rep. 6: 17, 1960. MedlineGoogle Scholar5. JAFFEHANDSCHUMACHERWELCH JJREAD: Studies on the carcinostatic activity in mice of 6-azauracil riboside (azauridine) in comparison with that of 6-azauracil. Yale J. Biol. Med. 30: 168, 1957. MedlineGoogle Scholar6. WELCHHANDSCHUMACHERFINCHJAFFECARDOSOCALABRESI ADRESCJJSSP: A synopsis of recent investigations of 6-azauridine (NSC-32074). Cancer Chemother. Rep. 9: 39, 1960. MedlineGoogle Scholar7. GOLDHALLSHNIDERSELAWRYCOLSKYOWENSDEDERICKHOLLANDBRINDLEYJONES GLTCBIOJAHMMJFCOR: Clinical study of 5-fluorouracil. Cancer Res. 19: 935, 1959. MedlineGoogle Scholar8. WILSON WL: Preliminary observations on use of 5-fluorouracil in human neoplasms. Med. Rec. Ann. 51: 829, 1958. Google Scholar9. CHAUDHURIMONTAGHEIDELBERGER NKBJC: Studies on fluorinated pyrimidines. III. The metabolism of 5-fluorouracil-2-C14 and 5-fluoroorotic-2-C14 acid in vivo. Cancer Res. 18: 318, 1958. MedlineGoogle Scholar10. HOROWITZSAUKKONENCHARGAFF JJJE: Effect of 5-fluorouracil on a uracil requiring mutant of E. coli. Biochim. Biophys. Acta 29: 222, 1958. CrossrefMedlineGoogle Scholar11. SAUKKONENGOODMANCHARGAFF JJFE: Patterns of cellular control, effect of 5-fluorouracil on metabolic events in bacteria infected with coliphage T2r+. Biochim. Biophys. Acta 44: 469, 1960. CrossrefMedlineGoogle Scholar12. BRESNICKHITCHINGS EG: Feedback control in Ehrlich ascites cells. Cancer Res. 21: 105, 1961. Google Scholar13. SKOLD O: Enzymic ribosidation and ribotidation of 5-fluorouracil by extracts of Ehrlichascites tumor. (Preliminary notes.) Biochim. Biophys. Acta 29: 651, 1958. CrossrefMedlineGoogle Scholar14. ZAMENHOFREINERDEGIOVANNIRICH SBRK: Introduction of unnatural pyrimidines into deoxyribonucleic acid of Escherichia coli. J. Biol. Chem. 219: 165, 1956. CrossrefMedlineGoogle Scholar15. BOSCHHARBERSHEIDELBERGER LEC: Studies on fluorinated pyrimidines. V. Effects on nucleic acid metabolism in vitro. Cancer Res. 18: 335, 1958. MedlineGoogle Scholar16. EIDENOFFKNOLLKLEIN MLJED: Effect of 5-fluorouracil on the incorporation of precursors into nucleic acid pyrimidines. Arch. Biochem. 71: 274, 1957. CrossrefMedlineGoogle Scholar17. COHENFLAKSBARNERLOEBLICHTENSTEIN SSJGHDMRJ: Mode of action of 5-fluorouracil and its derivatives. Proc. Nat. Acad. Sci. USA 44: 1004, 1958. CrossrefMedlineGoogle Scholar18. REICHERTMUELLER RG: Studies on unbalanced growth in tissue culture. Cancer Res. 20: 1584, 1960. MedlineGoogle Scholar19. HEIDELBERGERGHOBARBAKERMUKHERJEE CARKKL: Studies on fluorinated pyrimidines. X. In vivo studies on tumor resistance. Cancer Res. 20: 897, 1960. MedlineGoogle Scholar20. HEIDELBERGERKALDORMUKHERJEEDANNEBERG CGKLPB: Studies on fluorinated pyrimidines. XI. In vitro studies on tumor resistance. Cancer Res. 20: 903, 1960. MedlineGoogle Scholar21. CHAUDHURIMUKHERJEEHEIDELBERGER NKKLC: Studies on fluorinated pyrimidines. VII. Degradative pathway. Biochem. Pharmacol. 1: 328, 1958. CrossrefGoogle Scholar22. WHEELERALEXANDER GPJA: Searches for exploitable biochemical differences between normal and cancer cells. VIII. Catabolism of purines and purine nucleotides by sonicates. Cancer Res. 21: 407, 1961. MedlineGoogle Scholar23. CANELLAKIS ES: Pyrimidine metabolism. I. Enzymatic pathways of uracil and thymine degradation. J. Biol. Chem. 221: 315, 1956. CrossrefMedlineGoogle Scholar24. HEIDELBERGERCHAUDHURIWESTON CNKEL: The metabolism of 5-fluorouracil-2-C14 in humans. Proc. Amer. Ass. Cancer Res. 2: 306, 1958. Google Scholar25. WOLBERGCURRERI WHAR: Toxicity studies of 5-fluorouracil used as an adjunct to surgery. Cancer Chemother. Rep. 6: 16, 1960. MedlineGoogle Scholar26. WEISS AJ: Unpublished observations. Google Scholar27. TALLEY RW: Clinical evaluation of cancer chemotherapy with 5-fluorouracil. Cancer 14: 131, 1961. CrossrefMedlineGoogle Scholar28. WEISSJACKSON AJL: The effect of 5-fluorouracil upon carcinomas of the gastrointestinal tract and related organs. Amer. J. Gastroent. 35: 138, 1961. MedlineGoogle Scholar29. FOYEWILLETTHALLROTH LVFJBM: The potentiation of radiation effects with 5-fluorouracil. Cancer Chemother. Rep. 6: 12, 1960. MedlineGoogle Scholar30. WILSONDERENMILLS WLTLC: The use of 5-fluorouracil for carcinomas of the bladder. Fed. Proc. 18: 460, 1959. Google Scholar31. HOFFMANN-LA ROCHE, INC.: Collected data on 5-fluorouracil. Hoffmann-La Roche, Inc., Nutley, N. J. Google Scholar32. YOUNGELLISONSULLIVANLEVICKGOLBEYESCHERKAUFMANKARNOFSKYBURCHANAL CWRRRDSNRBGRDAJH: Evaluation of the therapeutic response of large bowel cancer to the fluorinated pyrimidines in relationship to clinical patterns. Proc. Amer. Ass. Cancer Res. 3: 164, 1960. Google Scholar33. HERTZBERGENSTALLIPSETTPRICEHILBISH RDMMBEBTF: Chemotherapy of choriocarcinoma and related trophoblastic tumors in women. Ann. N. Y. Acad. Sci. 80: 262, 1959. CrossrefMedlineGoogle Scholar34. SULLIVANMILLERSIKES RDEMP: Antimetabolite-metabolite combination cancer chemotherapy; effects of intra-arterial methotrexate-intramuscular citrovorum factor therapy in human cancer. Cancer 12: 1248, 1959. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: ARTHUR J. WEISS, M.D.; LAIRD G. JACKSON, M.D.; RALPH CARABASI, M.D.Affiliations: Philadelphia, PennsylvaniaRequests for reprints should be addressed to Arthur J. Weiss, M.D., Department of Medicine, Jefferson Medical College, Philadelphia 7, Pennsylvania. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byOptic neuritis induced by 5-fluorouracil chemotherapy: Case report and review of the literatureMajor Contributions towards Finding a Cure for Cancer through Chemotherapy: A Historical ReviewBilateral optic disc oedema and associated optic neuropathy in the setting of FOLFOX chemotherapyOcular presentations of breast cancerOcular Surface, Ocular Adnexal, and Lacrimal Complications Associated With the Use of Systemic 5-FluorouracilProstatakarzinomProstatakarzinomDoxorubicin, Mitomycin C and 5-Fluorouracil in the Treatment of Hormone Refractory Adenocarcinoma of the Prostate: A Southwest Oncology Group StudyMedical Management of Gastrointestinal CancerOcular complications of systemic cancer chemotherapyEditorial Comment on Hormonal Management of Stage D Carcinoma of the ProstateChemotherapie des inoperablen PankreaskarzinomsAdvanced Renal Cell Carcinoma: Natural History and Response to ChemotherapyNew drug development in head and neck oncologyTREATMENT OF ADVANCED BLADDER CANCER USING C/S-PLATINUMThe Chemotherapy of Bladder Carcinoma: Systemic TherapyTreatment of Metastatic Renal Cell CarcinomaThe Management of Advanced Bladder CarcinomaChemotherapeutic Management of Bladder CancerLiteraturverzeichnisMedical Treatment of Advanced Carcinoma of the Cervix. A ReviewCicatricial ectropion secondary to 5-fluorouracil therapyToxicity of Chemotherapeutic AgentsBiology, Diagnosis, and Chemotherapeutic Management of Pancreatic MalignancyThe integration of chemotherapy into a combined modality approach for cancer treatmentThe chemotherapy of urologic cancerTreatment of Stage IV Carcinoma of the ProstateA review of chemotherapy in gastric cancerNonhormonal chemotherapy of endometrial adenocarcinoma: A reviewIntegration of chemotherapy into combined modality treatment of solid tumorsEndometrial cancer: Approach to development of effective chemotherapyChemotherapy of adenocarcinoma of the kidneyNon-hormonal cytotoxic agents in the treatment of prostatic adenocarcinomaA major cause of gastrointestinal hemorrhage in patients with malignant diseaseTreatment of cancer with weekly intravenous 5-fluorouracil.Study by the Western Cooperative Cancer Chemotherapy Group (WCCCG)Lung Cancer: Perspectives and ProspectsPAUL P. CARBONE, M.D., JOHN K. FROST, M.D., ALVAN R. FEINSTEIN, M.D., GEORGE A. HIGGINS JR., M.D., OLEG S. SELAWRY, M.D.5-FluorouracilTreatment of cancer with weekly intravenous 5-fluorouracil5-FLUOROURACILThe Effect of Five-Fluorouracil on Rectal MucosaChemotherapy for CancerPreliminary observations on carcinoma of the cervix treated with 5-fluorouracilTHE MANAGEMENT OF THE PATIENT WITH INOPERABLE MALIGNANT DISEASECarcinoma of the colon and rectumThe Granulocyte Response to an Endotoxin (Pyrexal) as a Measure of Functional Marrow Reserve in Cancer ChemotherapyMARTIN E. FINK, M.D., PAUL CALABRESI, M.D.Treatment of Breast Cancer with 5-FluorouracilHORACE K. IVY, M.D.Chemotherapy of Cancer of the Alimentary TractCurrent Considerations in Surgery of Cancer of the Colon and RectumThe treatment of recurrent or metastatic breast cancer with emphasis on the use of 5-fluorouracil 1 November 1961Volume 55, Issue 5Page: 731-741KeywordsAdenocarcinomaDrugsHepatocellular carcinomaLiverMucous membranesPurines ePublished: 1 December 2008 Issue Published: 1 November 1961 PDF downloadLoading ...